SCI Pharmtech Corp. AI Stock Analysis
SCI Pharmtech Corp. (4119) AI Stock Analysis
SCI Pharmtech Corp.
(TWSE:4119)
SCI Pharmtech scores below average overall. The dominant driver is weak financial performance: a sharp margin squeeze, an ~80% drop in net income, return on equity near 2%, and persistently negative free cash flow driven by heavy capital spending. The conservative balance sheet — low debt-to-equity of 0.18 and equity funding nearly 80% of assets — provides meaningful downside protection and the flexibility to fund the ongoing expansion. Technicals add to the caution, with the price trading below its key moving averages and a negative MACD, although oversold momentum readings hint at possible stabilisation. Valuation is the weakest supporting factor, with a P/E above 100 reflecting depressed earnings and a modest 1.5% dividend yield. The investment case rests on whether the capacity build-out translates into higher-margin revenue and positive free cash flow.
SCI Pharmtech Corp. (4119) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 6.07B
- Dividend Yield
- 1.55%
- Average Volume (3M)
- 169.26K
- Price to Earnings (P/E)
- 95.7
- Beta (1Y)
- 0.30
- Revenue Growth
- -18.83%
- EPS Growth
- -87.54%
- Country
- TW
- Employees
- 202
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
SCI Pharmtech Corp. Business Overview & Revenue Model
Company Description
SCI Pharmtech, Inc., founded in 1987 and based in Taoyuan City, Taiwan, specializes in the comprehensive lifecycle of pharmaceutical components. The company's core operations involve the research and development, manufacturing, and global distributio...
SCI Pharmtech Corp. Financial Statement Overview
Summary
A strong, conservatively financed balance sheet (equity funds ~78% of assets, debt-to-equity of 0.18) is offset by weak and volatile earnings and cash generation. Revenue slipped to NT$1.34B, gross margin compressed to 23.8%, and net income fell roughly 80% to NT$107M, dragging return on equity down to about 2%. Operating cash flow dropped to NT$220M and free cash flow was negative NT$390M, the fifth negative year in six, as heavy capacity investment continues to absorb cash. The company is financially stable but currently under-earning on its expanded asset base.
Income Statement
42NeutralBalance Sheet
74PositiveCash Flow
45Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.26B | 1.34B | 1.52B | 1.20B | 899.74M | 864.22M |
| Gross Profit | 281.04M | 319.47M | 410.67M | 350.32M | 291.18M | 208.09M |
| EBITDA | 360.24M | 408.21M | 909.92M | 515.77M | 492.07M | 142.81M |
| Net Income | 60.12M | 107.37M | 534.68M | 294.72M | 308.78M | 55.70M |
Balance Sheet | ||||||
| Total Assets | 6.93B | 6.89B | 7.20B | 6.69B | 4.96B | 4.19B |
| Cash, Cash Equivalents and Short-Term Investments | 84.07M | 74.80M | 692.76M | 1.03B | 264.37M | 692.63M |
| Total Debt | 1.06B | 987.18M | 990.39M | 1.04B | 545.38M | 2.15M |
| Total Liabilities | 1.62B | 1.49B | 1.72B | 1.59B | 1.33B | 869.26M |
| Stockholders Equity | 5.31B | 5.39B | 5.48B | 5.10B | 3.63B | 3.32B |
Cash Flow | ||||||
| Free Cash Flow | -174.44M | -389.68M | -86.12M | -813.59M | -871.02M | -494.70M |
| Operating Cash Flow | 223.88M | 220.32M | 860.52M | 215.77M | 296.56M | 280.28M |
| Investing Cash Flow | -380.21M | -512.92M | -1.01B | -866.20M | -1.01B | -539.56M |
| Financing Cash Flow | -11.53M | -229.15M | -210.84M | 1.43B | 547.12M | -41.52M |
SCI Pharmtech Corp. Peers Comparison
Overall Rating
TW:416670Outperform
TW:173464Neutral
TW:474664Neutral
TW:416760Neutral- TW:411948Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4166 | 70Outperform | TWD 5.47B | 22.78 | ― | ― | ― | ― |
| TW:1734 | 64Neutral | TWD 6.07B | 17.33 | ― | 3.13% | 2.44% | -3.96% |
| TW:4746 | 64Neutral | TWD 5.43B | 11.42 | ― | 6.61% | -2.71% | ― |
| TW:4167 | 60Neutral | TWD 6.30B | 7.86 | ― | 4.18% | -0.05% | 64.82% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4119 | 48Neutral | TWD 5.85B | 95.69 | ― | 1.55% | -18.83% | -87.54% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4119 | SCI Pharmtech Corp. | 48.50 | -0.61 | -1.25% | |
| TW:1734 | Sinphar Pharmaceutical Co. Ltd. | 30.15 | 1.76 | 6.19% | |
| TW:4166 | Orient Pharma Co., Ltd. | 22.55 | -2.05 | -8.33% | |
| TW:4167 | Savior Lifetec Corp. | 19.25 | 2.48 | 14.77% | |
| TW:4746 | Formosa Laboratories, Inc. | 45.40 | -15.89 | -25.92% | |
| TW:7754 | Annji Pharmaceutical Co., Ltd. | 69.40 | 24.75 | 55.45% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026